Functionality, quality of life improve in tardive dyskinesia with valbenazine

Patients with tardive dyskinesia experienced improvements in quality of life and functionality across 24 weeks of treatment with valbenazine, according to a study published in CNS Spectrums. Valbenazine (Ingrezza; Neurocrine Biosciences) is one of two vesicular monoamine transporter 2 inhibitors approved for tardive dyskinesia (TD) treatment, Christoph U. Correll, MD, professor of psychiatry and